Business Description
Rigel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7665596034
Share Class Description:
FRA:RI2: Ordinary SharesDescription
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.02 | |||||
| Equity-to-Asset | -0.11 | |||||
| Debt-to-Equity | -4.12 | |||||
| Debt-to-EBITDA | 4.41 | |||||
| Interest Coverage | 1.21 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -10.35 | |||||
| Beneish M-Score | -2.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.4 | |||||
| 3-Year EBITDA Growth Rate | 15.9 | |||||
| 3-Year EPS without NRI Growth Rate | 8 | |||||
| 3-Year FCF Growth Rate | 27.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 23.55 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.38 | |||||
| 9-Day RSI | 67.18 | |||||
| 14-Day RSI | 68.02 | |||||
| 6-1 Month Momentum % | 60.29 | |||||
| 12-1 Month Momentum % | 32.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | |||||
| Quick Ratio | 1.87 | |||||
| Cash Ratio | 1.13 | |||||
| Days Inventory | 136.18 | |||||
| Days Sales Outstanding | 65.4 | |||||
| Days Payable | 150.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -0.92 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.43 | |||||
| Operating Margin % | 6.04 | |||||
| Net Margin % | 2.47 | |||||
| FCF Margin % | 6.34 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 3.1 | |||||
| ROIC % | 14.02 | |||||
| ROC (Joel Greenblatt) % | 1380.85 | |||||
| ROCE % | 17.32 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 120.04 | |||||
| Forward PE Ratio | 27.2 | |||||
| PE Ratio without NRI | 120.04 | |||||
| PEG Ratio | 5.26 | |||||
| PS Ratio | 3.08 | |||||
| Price-to-Free-Cash-Flow | 47.52 | |||||
| Price-to-Operating-Cash-Flow | 45.94 | |||||
| EV-to-EBIT | 41.31 | |||||
| EV-to-Forward-EBIT | 21.97 | |||||
| EV-to-EBITDA | 35.52 | |||||
| EV-to-Forward-EBITDA | 21.97 | |||||
| EV-to-Revenue | 3.08 | |||||
| EV-to-Forward-Revenue | 2.64 | |||||
| EV-to-FCF | 46.87 | |||||
| Price-to-DCF (Earnings Based) | 4.45 | |||||
| Price-to-DCF (FCF Based) | 1.6 | |||||
| Price-to-Median-PS-Value | 0.53 | |||||
| Earnings Yield (Greenblatt) % | 2.42 | |||||
| FCF Yield % | 2.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rigel Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 144.049 | ||
| EPS (TTM) (€) | 0.198 | ||
| Beta | 1.98 | ||
| Volatility % | 92.92 | ||
| 14-Day RSI | 68.02 | ||
| 14-Day ATR (€) | 1.234527 | ||
| 20-Day SMA (€) | 21.23 | ||
| 12-1 Month Momentum % | 32.19 | ||
| 52-Week Range (€) | 7.705 - 26.8 | ||
| Shares Outstanding (Mil) | 17.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rigel Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rigel Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rigel Pharmaceuticals Inc Frequently Asked Questions
What is Rigel Pharmaceuticals Inc(FRA:RI2)'s stock price today?
The current price of FRA:RI2 is €25.60. The 52 week high of FRA:RI2 is €26.80 and 52 week low is €7.71.
When is next earnings date of Rigel Pharmaceuticals Inc(FRA:RI2)?
The next earnings date of Rigel Pharmaceuticals Inc(FRA:RI2) is 2025-03-05 Est..
Does Rigel Pharmaceuticals Inc(FRA:RI2) pay dividends? If so, how much?
Rigel Pharmaceuticals Inc(FRA:RI2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers